Overview

Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study is a phase 1 single dose escalation study of AMG 157 in healthy subjects and subjects with moderate to severe atopic dermatitis. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of AMG 157.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen